Olympiad Research LP Invests $448,000 in Exscientia plc (NASDAQ:EXAI)

Olympiad Research LP acquired a new position in Exscientia plc (NASDAQ:EXAI) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 91,809 shares of the company’s stock, valued at approximately $448,000.

Several other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Exscientia by 66.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock valued at $47,000 after acquiring an additional 3,821 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Exscientia in the 3rd quarter valued at about $77,000. Novo Holdings A S acquired a new position in shares of Exscientia during the second quarter valued at approximately $66,742,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Exscientia in the second quarter worth approximately $256,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Exscientia during the 2nd quarter worth $54,000. 41.58% of the stock is currently owned by hedge funds and other institutional investors.

Exscientia Trading Up 0.8 %

NASDAQ:EXAI opened at $5.35 on Thursday. The stock has a market cap of $646.76 million, a P/E ratio of -4.08 and a beta of 0.83. Exscientia plc has a 1 year low of $3.80 and a 1 year high of $7.91. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.93 and a current ratio of 5.93. The stock has a 50-day simple moving average of $5.01 and a 200-day simple moving average of $5.10.

Exscientia (NASDAQ:EXAI) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. The company had revenue of $5.60 million for the quarter. As a group, analysts anticipate that Exscientia plc will post -1.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EXAI. Barclays reissued an “equal weight” rating and issued a $5.00 price objective on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Exscientia in a research note on Friday, August 9th.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.